Tisagenlecleucel outcomes study in relapsed B-cell blood cancers
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This study looks at how safe and effective tisagenlecleucel is for people in Brazil who have certain B-cell blood cancers that came back or did not respond to treatment. You may be included if you already received tisagenlecleucel outside a research study and can consent to share your medical data.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have received a tisagenlecleucel infusion (outside a clinical trial, or as an out-of-spec use).
- You must be willing to sign informed consent to let the study collect your medical information.
- You have relapsed or refractory B-cell ALL and received tisagenlecleucel (ages 0–17 or 18–25).
- OR you have relapsed or refractory Diffuse Large B-cell Lymphoma (DLBCL) and received tisagenlecleucel (age 18+).
- OR you have relapsed or refractory Follicular Lymphoma (FL) and received tisagenlecleucel (age 18+).
- You cannot be included if you received tisagenlecleucel as part of another interventional clinical trial.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at using tisagenlecleucel, a cell therapy, when the final product does not meet routine “commercial release” quality standards. It focuses on whether it can still be given safely and effectively to people with serious or life-threatening illness.
This study follows patients receiving CAR-T cell therapy—an advanced treatment where immune cells are modified to fight leukemia—for acute lymphoblastic leukemia (ALL) that has returned or didn't respond to initial treatment. The trial tracks how well the therapy works and its safety in both children and adults.
This Phase 2 study tests whether adding or switching drug treatments after CAR T-cell therapy can improve outcomes for people with certain aggressive lymphomas that have come back or did not respond. It mainly looks at who remains disease-stable/partly improved after CAR T and what treatment approach works best next.
This early-phase trial tests an injected “CAR T” cell therapy made to attack CD19-positive blood cancers that have come back or did not respond. If you qualify, the study checks whether the treatment can help control the cancer and is safe enough to study further.
This study looks at the real-world results of treating certain B-cell blood cancers in children and young adults with commercially available immunotherapy. It may help doctors better understand how these treatments work for patients after relapse or when they need additional therapy.
This study looks at people who developed a new T-cell cancer after receiving the CAR-T therapy tisagenlecleucel (Kymriah). Researchers want to understand these rare cancers by testing stored tumor samples. You may be eligible if you had tisagenlecleucel and were later diagnosed with a T-cell malignancy.
Hear when a new Diffuse Large B Cell Lymphoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.